Selected publications for recent five years

*corresponding author

2016

  1. Sugiyama M, and Kanto T*. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1. Hepatology. 2016 Sep;64(3):979-82.
  2. Nishitsuji H*,Ujino S, Yoshio S, Sugiyama M, Mizokami M, Kanto T, Shimotohno K. Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression.Proc Natl AcadSci USA. 113(37): 10388-10393, 2016
  3. Ujino S*,Nishitsuji H, Hishiki T, Sugiyama K, Takaku H, Shimotohno K*. Hepatitis C virus utilizes VLDLR as a novel entry pathway.Proc Natl AcadSci USA. 113(1): 188-193, 2016
  4. Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M*. Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis.Sci Rep. 2016 Apr 19;6:24767.

2015

  1. Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M, Kanto T*. Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology. 2015 Oct 12.
  2. Mizokami M*, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M.Ledipasvir and Sofosbuvir Fixed-Dose Combination with and without Ribavirin for 12 Weeks in Treatment-Naive and Previously Treated Japanese Patients with Genotype 1 Hepatitis C: An Open-Label, Randomised, Phase 3 Trial.Lancet Infect Dis15 (6): 645-532015.06
  3. Nishitsuji H*, Ujino S, Shimizu Y, Harada K, Zhang J, Sugiyama M, Mizokami M, Shimotohno K*. Novel reporter system to monitor early stages of the hepatitis B virus life cycle.Cancer Sci. 106(11): 1616-1624, 2015
  4. Nishida N, Ohashi J, Sugiyama M, Tsuchiura T, Yamamoto K, Hino K, Honda M, Kaneko S, Yatsuhashi H, Koike K, Yokosuka O, Tanaka E, Taketomi A, Kurosaki M, Izumi N, Sakamoto N, Eguchi Y, Sasazuki T, Tokunaga K, Mizokami M*. Effects of HLA-DPB1 genotypes on chronic hepatitis B infection in Japanese individuals. Tissue Antigens. 2015 Dec;86(6):406-12.
  5. Miyadera H*, Bungener LB, Kusano S, Yokoyama S, Tokunaga K, Hepkema BG. Questionable expression of unstable DQ heterodimer containing HLA-DQA1*01:07 Tissue Antigens(2015) 86: 413-418.
  6. Miyadera H*, Tokunaga K. Associations of human leukocyte antigens (HLA) with autoimmune diseases: Challenges in identifying the mechanism. J Hum Genet(2015) 60:697-702.
  7. Miyadera H*, Ohashi J, LernmarkÅ, Kitamura T, Tokunaga K. Cell-surface MHC density profiling revealsinstability of autoimmunity-associated HLA. J Clin Invest(2015) 125: 275–291

2014

  1. Shimizu Y, Nishitsuji H, Marusawa H, Ujino S, Takaku H, Shimotohno K*. The RNA-editing enzyme APOBEC1 requires heterogeneous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA. J Biol Chem. 289(38): 26226-26238, 2014
  2. Khudayberganova D, Sugiyama M*, Masaki N, Nishida N, Mukaide M, Sekler D, Latipov R, Nataliya K, Dildora S, Sharapov S, Usmanova G, Raxmanov M, Musabaev E, Mizokami M. IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan. PLoS One. 2014 Mar 24;9(3):e93011.
  3. Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramine S, Matsui T, Ito K, Korenaga M, Imamura M, Masaki N, Mizokami M*. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. J Gastroenterol. Jan;49(1):126-37. 2014
  4. Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M*. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J GastroenterolHepatol. 2014
  5. Nishino J, Sugiyama M, Nishida N, Tokunaga K, Mizokami M, Mano S*. The interaction of a single-nucleotide polymorphism with age on response to interferon-α and ribavirin therapy in female patients with hepatitis C infection. J Med Virol. 2014 Jul;86(7):1130-3.
  6. Ueta M*, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H,Miyadera H, Sugiyama E, Maekawa K, Nakamura R, Nagato M, Aihara M, Matsunaga K, Takahashi Y, Furuya H, Muramatsu M, Ikezawa Z, Kinoshita S. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep.(2014) 4: 4862.
  7. Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, Han KH, Matsuura K, Tanaka Y, Kurosaki M, Asahina Y, Izumi N, Kang JH, Hige S, Ide T, Yamamoto K, Sakaida I, Murawaki Y, Itoh Y, Tamori A, Orito E, Hiasa Y, Honda M, Kaneko S, Mita E, Suzuki K, Hino K, Tanaka E, Mochida S, Watanabe M, Eguchi Y, Masaki N, Murata K, Korenaga M, Mawatari Y, Ohashi J, Kawashima M, Tokunaga K, Mizokami M*. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. PLoS One. 2014 Feb 10;9(2):e86449.

2013

  1. Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M*. Thromboxane A2 Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice With Humanized Livers.Gastroenterology. 145: 658-667, 2013
  2. Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K*. Hepatitis C Virus Infection Induces Inflammatory Cytokines and Chemokines Mediated by the Cross Talk between Hepatocytes and Stellate Cells.J Viol 87: 8169-8178, 2013
  3. Sunbul M, Sugiyama M*, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. MicrobiolImmunol. 2013 Feb;57(2):122-9.
  4. Isogai H, Miyadera H,Ueta M, Sotozono C, Kinoshita S, Tokunaga K, and Hirayama N*. In silico risk assessment of HLA-A*02:06-associated Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) caused by cold medicine ingredients.J. Toxicol.(2013) Article ID 514068

2012

  1. Sugiyama M, Kimura T, Naito S, Mukaide M, Shinauchi T, Ueno M, Ito K, Murata K, Mizokami M*. Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon. Hepatol Res. 2012 Nov;42(11):1089-99.
  2. Han F, Lin L, Li J, Dong SX, An P, Zhao L, Liu NY, Li QY, Yan H, Gao ZC, Faraco J, Strohl KP, Liu X, Miyadera H, Mignot E*. HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens(2012) 80:328-335.
  3. Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M*. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One. 2012;7(6):e39175.
  4. Nishida N, Mawatari Y, Sageshima M, Tokunaga K*. Highly parallel and short-acting amplification with locus-specific primers to detect single nucleotide polymorphisms by the DigiTag2 assay. PLoS One. 2012;7(1):e29967.

　National Center for Global 　Health and Medicine
　Research Institute
　Genome Medical Science 　Project

　〒272-8516
　1-7-1 Kounodai,
　Ichikawa-shi, Chiba
　TEL 047-372-3501
　FAX 047-375-4766